EUVIMEDEUVIMED entdecken
Fallbericht

Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis

Timothy Seers iD, Helen Quah, Dalia Ludwig, Mahdad Noursadeghi, Michael Brown, David Aj Moore, Jessica J Manson

British Journal of Hospital Medicine · 2025

DOI: 10.12968/hmed.2024.0462 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Hospital Medicine, 2025. Verfasst von Timothy Seers und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Adalimumab, Lymphohistiocytosis, Hemophagocytic, Latent Tuberculosis, Tuberculosis, Miliary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the case of a 63-year-old man presenting with fevers, hyperferrintinaemia and pancytopaenia. He was known to have psoriatic arthritis, managed with adalimumab and methotrexate. Haemophagocytic lymphohistiocytosis (HLH) was diagnosed, and he was treated with intravenous anakinra whilst searching for an aetiology. Despite previous treatment for latent tuberculosis, he developed changes typical for miliary tuberculosis and was started on antituberculosis therapy; whole genome sequencing later demonstrated isoniazid monoresistance. This case demonstrates both the importance of recognising Mycobacterium tuberculosis as a trigger of HLH, and also the risk of latent tuberculosis treatment failure in the setting of monoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabLymphohistiocytosis, HemophagocyticLatent TuberculosisTuberculosis, MiliaryHumansMaleMiddle AgedAntitubercular AgentsArthritis, PsoriaticAntirheumatic AgentsMycobacterium tuberculosisInterleukin 1 Receptor Antagonist ProteinIsoniazid

Stichwörter der Autor:innen

adalimumabcase reporthaemophagocytic lymphohistiocytosisisoniazid monoresistancetuberculosis

Substanzen

AdalimumabAntitubercular AgentsAntirheumatic AgentsInterleukin 1 Receptor Antagonist ProteinIsoniazid

Autor:innen und Institutionen

  • The Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, UK.
  • Department of Acute Medicine, Whittington Health NHS Trust, London, UK.
  • Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.
  • North Central London Tuberculosis Hub (South), Whittington Health NHS Trust, London, UK.

ORCID-Profile: Timothy Seers

Zitieren

APA

Seers, T., Quah, H., Ludwig, D., Noursadeghi, M., Brown, M., Moore, D. A., & Manson, J. J. (2025). Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2024.0462

Vancouver

Seers T, Quah H, Ludwig D, Noursadeghi M, Brown M, Moore DA, et al. Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis. British Journal of Hospital Medicine. 2025. doi:10.12968/hmed.2024.0462

BibTeX
@article{Seers2025,
  author = {Seers, Timothy and Quah, Helen and Ludwig, Dalia and Noursadeghi, Mahdad and Brown, Michael and Moore, David Aj and Manson, Jessica J},
  title = {Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis},
  journal = {British Journal of Hospital Medicine},
  year = {2025},
  doi = {10.12968/hmed.2024.0462}
}
Kostenlos starten →